Sanofi — 13F Holdings & Portfolio

CIK 1121404 · latest 13F-HR filed 2026-05-07

Sanofi manages $336.0M in 13F-reported U.S. long-equity assets across 9 reported positions as of its 2026-03-31 13F-HR filing. Its largest disclosed positions are MGTX (31.44%), INBX (23.17%), NVAX (16.67%). Quarter over quarter (versus its 2025-12-31 filing) the fund opened 1 new position, exited 0, added to 5, and trimmed 3.

AUM is the long-equity portion reported on Form 13F-HR. Excludes short positions, cash, foreign holdings, and non-13F assets. For informational purposes only — not investment advice.

Loading holdings…
AUM

$336.0M

Long-equity book

Holdings

9

Distinct positions

Period

2026-03-31

Filed 2026-05-07

Q/Q Activity

+1 / −0 / ↑5 / ↓3

vs 2025-12-31

Firm Profile & Key People
Name Title / Status Ownership Type

Top Adds (vs prior quarter)

  • Novavax$9.8M +21.1%
  • MeiraGTx Holdings plc$8.7M +8.9%
  • MapLight Therapeutics Inc.$2.5M +15.7%
  • Eledon$1.3M +104.0%
  • Q32 Bio Inc.$756.7K +93.4%
Show all 5

Top Trims

  • Inhibrx Biosciences, Inc.-$13.6M -14.9%
  • AnaptysBio-$9.5M -23.7%
  • Immuneering Corp-$3.5M -19.9%
Show all 3

New Positions

  • Agomab Therapeutics NV$29.2M
Show all 1

Exited Positions

  • No exits this quarter.
Show all 0
All Holdings

Rows tagged Call or Put are options positions, not stock. Per SEC Form 13F-HR, Value shows the notional value of the underlying (shares covered × underlying price), not the option premium. Shares is the number of underlying shares covered (divide by 100 for contract count).

# Issuer Symbol CUSIP Value Weight Shares Type
1 MeiraGTx Holdings plc MGTX G59665102 $105.6M 31.44% 12,197,737 SH
2 Inhibrx Biosciences, Inc. INBX 45720N103 $77.8M 23.17% 1,157,926 SH
3 Novavax NVAX 670002401 $56.0M 16.67% 6,880,481 SH
4 AnaptysBio ANAB 032724106 $30.4M 9.04% 821,917 SH
5 Agomab Therapeutics NV AGMB 00860C102 $29.2M 8.69% 2,783,096 SH
6 MapLight Therapeutics Inc. MPLT 56565P103 $18.5M 5.52% 912,041 SH
7 Immuneering Corp IMRX 45254E107 $14.3M 4.25% 2,708,559 SH
8 Eledon ELDN 28617K101 $2.5M 0.75% 814,980 SH
9 Q32 Bio Inc. QTTB 746964105 $1.6M 0.47% 244,083 SH
Filing History
Period Filed AUM Holdings Accession
2026-03-31 2026-05-07 $336.0M 9 0001193125-26-210525
2025-12-31 2026-02-11 $310.4M 8 0001193125-26-045633